ADD1

ADD1 encodes α-adducin, a multifunctional protein that operates both as a cytoskeletal actin-capping protein regulating membrane-cytoskeleton interactions and, through its SREBP1c isoform, as a basic helix-loop-helix-leucine zipper transcription factor controlling lipogenic and adipogenic gene expression. As a transcription factor (ADD1/SREBP1c), it binds both E-box and SRE-1 DNA motifs—a dual specificity governed by a single atypical tyrosine in its basic region—to activate fatty acid synthase, 6-phosphogluconate dehydrogenase, PGC1α, and CHRDL1, and it stimulates PPARγ activity by producing endogenous lipid ligands; its transcriptional output is negatively regulated by GSK3β-mediated phosphorylation and by inhibitory interactions with Id2/Id3 and Twist2 (PMID:7739539, PMID:9539737, PMID:15466874, PMID:10585876, PMID:14654692). In its cytoskeletal capacity, ADD1's actin-capping activity is required for consolidation of synaptic AMPA receptor content and associative memory, and upon S-nitrosylation signaling it translocates to the nucleus where it recruits a MATR3/ADAR1 complex to drive A-to-I RNA editing of cathepsin B mRNA (PMID:22307086, PMID:37156877). Loss-of-function ADD1 variants in humans cause corpus callosum dysgenesis, ventriculomegaly, and intellectual disability, phenotypes recapitulated in Add1 knockout mice (PMID:34906466).

1. 1993 High

   The identification of ADD1 as a bHLH-LZ transcription factor that binds the fatty acid synthase E-box and activates transcription in adipocytes established the gene's primary molecular identity as a lipogenic transcriptional regulator.

   Evidence Oligonucleotide screening of adipocyte cDNA library with CAT reporter assays and DNA-binding analysis

   PMID:8336713

   Open questions at the time

   • Mechanism of differentiation-dependent activation not resolved
   • Relationship to SREBP family not yet established
2. 1995 High

   Demonstrating that a single tyrosine in the basic region confers dual E-box/SRE-1 DNA-binding specificity resolved how one transcription factor can regulate both cholesterol and fatty acid pathway promoters.

   Evidence Site-directed mutagenesis with PCR-amplified binding analysis and CAT reporter assays

   PMID:7739539

   Open questions at the time

   • Structural basis for tyrosine-mediated dual recognition not determined at atomic resolution
   • In vivo significance of dual specificity not tested
3. 1998 High

   Showing that ADD1/SREBP1c activates PPARγ by producing a secreted endogenous lipid ligand that displaces thiazolidinedione revealed a feed-forward lipogenic circuit linking SREBP1c to nuclear receptor activation.

   Evidence Gal4-LBD fusion reporter assays, conditioned-medium transfer, and radioligand displacement binding assay

   PMID:9539737

   Open questions at the time

   • Chemical identity of the endogenous PPARγ ligand not determined
   • Physiological relevance in intact adipose tissue not shown
4. 1999 High

   Identification of Id2/Id3 as physical interactors that inhibit ADD1/SREBP1c DNA binding established a dominant-negative regulatory mechanism for lipogenic transcription.

   Evidence EMSA, co-immunoprecipitation of in vitro-translated proteins, and CAT reporter assays in adipocytes

   PMID:10585876

   Open questions at the time

   • In vivo relevance of Id-mediated repression in lipid metabolism not tested
   • Stoichiometry of Id–SREBP1c complexes unknown
5. 2003 High

   Twist2 was found to repress ADD1/SREBP1c by physical interaction and reduced DNA binding in an HDAC-dependent manner, revealing a second class of bHLH-mediated transcriptional repression targeting lipogenesis.

   Evidence Yeast two-hybrid screen, co-immunoprecipitation, luciferase reporters, and HDAC inhibitor rescue

   PMID:14654692

   Open questions at the time

   • Which specific HDACs are recruited to the Twist2–SREBP1c complex is unknown
   • Physiological context for Twist2–SREBP1c antagonism not defined in vivo
6. 2004 High

   Demonstrating that GSK3β phosphorylates ADD1/SREBP1c and suppresses its transcriptional activity post-translationally identified an insulin-responsive kinase switch controlling lipogenic gene expression.

   Evidence In vitro and in vivo kinase assays, GSK3 inhibitor treatment, luciferase reporters, cycloheximide chase

   PMID:15466874

   Open questions at the time

   • Specific phosphorylation sites mapped by GSK3β on SREBP1c not fully characterized
   • Interplay between GSK3β phosphorylation and proteasomal degradation not resolved
7. 2009 Medium

   ChIP evidence that β-adrenergic stimulation recruits ADD1/SREBP1c to a conserved E-box in the PGC1α promoter connected lipogenic transcription factor activity to thermogenic gene regulation in brown adipocytes.

   Evidence Chromatin immunoprecipitation and luciferase reporter assays in brown adipocytes treated with adrenergic agonist

   PMID:19962449

   Open questions at the time

   • Whether ADD1/SREBP1c is necessary for cold-induced PGC1α expression in vivo is untested
   • Mechanism linking β-adrenergic signaling to SREBP1c chromatin recruitment not elucidated
8. 2012 High

   Cross-species genetic studies established that α-adducin's actin-capping activity is required for synaptic AMPA receptor retention and memory consolidation, separating its cytoskeletal function from its transcription factor role.

   Evidence C. elegans loss-of-function genetics, live GLR-1 imaging, olfactory learning assays, and human ADD1 rescue

   PMID:22307086

   Open questions at the time

   • Mechanism by which actin-capping stabilizes AMPA receptors at postsynaptic sites not defined
   • Whether mammalian synaptic plasticity uses the same splice-form dependence is unknown
9. 2012 Medium

   Add1 knockout mice displaying hyperkyphosis, megaesophagus, and reduced peripheral nerve axon numbers revealed non-erythroid developmental roles for α-adducin.

   Evidence Targeted gene deletion in mice with histological and morphological analysis

   PMID:22926980

   Open questions at the time

   • Strain dependence of phenotypes not mechanistically explained
   • Cell-autonomous versus non-autonomous roles of ADD1 in these tissues not distinguished
10. 2021 High

    Human genetic evidence that loss-of-function ADD1 variants cause corpus callosum dysgenesis and intellectual disability, recapitulated in knockout mice, established ADD1 as a Mendelian disease gene for neurodevelopmental malformation.

    Evidence Exome sequencing in affected families, super-resolution imaging, ADD1-ADD2 dimerization assay, Add1 knockout mouse phenotyping

    PMID:34906466

    Open questions at the time

    • How disrupted ADD1–ADD2 dimerization leads to corpus callosum dysgenesis at the cellular level is unknown
    • Whether heterozygous carriers show intermediate phenotypes is not addressed
11. 2023 High

    Discovery that dephosphorylated ADD1 translocates to the nucleus and recruits a MATR3/ADAR1 complex for A-to-I RNA editing of CTSB mRNA revealed an unexpected nuclear function for the cytoskeletal protein in RNA processing.

    Evidence S-nitrosylation assay, subcellular fractionation, co-immunoprecipitation of ADD1–MATR3–ADAR1, RNA editing sequencing, mRNA stability assay

    PMID:37156877

    Open questions at the time

    • Whether ADD1 recruits MATR3/ADAR1 to other mRNA targets beyond CTSB is unknown
    • Signal that triggers ADD1 dephosphorylation downstream of S-nitrosylation not fully delineated

• It remains unresolved how the cytoskeletal and transcriptional functions of ADD1 are coordinated in the same cell, whether ADD1-dependent RNA editing extends to a broad set of transcripts, and what the structural basis is for the ADD1–ADD2 dimer in neurodevelopment.
• No structural model for the ADD1–ADD2 heterodimer
• Genome-wide identification of ADD1-dependent RNA editing targets not performed
• Integration of cytoskeletal versus transcriptional versus RNA-editing functions in a unified signaling framework is lacking